Literature DB >> 18161402

Behavior of vascular endothelial growth factor and erythropoietin throughout the menstrual cycle in healthy women.

Chiara Caccamo1, Lorena Nostro, Giovanna Giorgianni, Stefania Mondello, Eleonora Crascì, Nicola Frisina, Michele Buemi.   

Abstract

OBJECTIVE: To evaluate any correlations between erythropoietin (EPO) and vascular endothelial growth factor (VEGF) levels in the serum and the menstrual fluid of healthy women during the different phases of the menstrual cycle. STUDY
DESIGN: Blood samples from 25 healthy female volunteers were obtained for serum VEGF and EPO detection on the 1st, 7th, 14th, 21st and 25th days of the menstrual cycle. Menstrual fluid samples for VEGF and EPO detection were obtained on the 1st and 4th days of menstruation.
RESULTS: Circulating VEGF levels were found to increase in a stage-dependent cyclic manner. The mean VEGF concentration in menstrual blood on the 1st day of the cycle was significantly higher than the mean plasma value and was reduced to a significant extent on the 4th day of the cycle. We found no significant changes in serum EPO levels. Mean EPO concentration detected in menstrual blood was comparable to those in serum blood either on the 1st or 4th day of the menstrual cycle.
CONCLUSION: During menstruation, a local production of VEGF occurs independent of systemic production, thus sustaining angiogenic activity in autonomous, independent ways. Our findings demonstrate the presence of an "open compartment" that reflects the systemic pattern of EPO at the uterine level that allows us to speculate on different effects beyond the angiogenic action of EPO.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18161402

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  2 in total

1.  Soluble VEGF receptor 1 promotes endothelial injury in children and adolescents with lupus nephritis.

Authors:  Monika Edelbauer; Sudhir Kshirsagar; Magdalena Riedl; Heiko Billing; Burkhard Tönshoff; Dieter Haffner; Jörg Dötsch; Gottfried Wechselberger; Lutz T Weber; Elisabeth Steichen-Gersdorf
Journal:  Pediatr Nephrol       Date:  2011-12-07       Impact factor: 3.714

2.  Salivary VEGF: a non-invasive angiogenic and lymphangiogenic proxy in head and neck cancer prognostication.

Authors:  Tahwinder Upile; Waseem Jerjes; Panagiotis Kafas; Shash Harini; Sandeep U Singh; Marcel Guyer; Melissa Bentley; Holger Sudhoff; Colin Hopper
Journal:  Int Arch Med       Date:  2009-04-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.